An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies.
- DOI
- 10.3389/fimmu.2025.1601670
- Published
- 2025-08-08
- Container
- Front Immunol
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2025.1601670,
title = {An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies.},
author = {Mazein A and Lopata O and Reiche K and Sewald K and Alb M and Sakellariou C and Gogesch P and Morgan H and Neuhaus V and Pham NN and Sommer C and Perkins E and Fogal B and Shoaib M and Schneider R and Satagopam V and Ostaszewski M.},
year = {2025},
journal = {Front Immunol},
doi = {10.3389/fimmu.2025.1601670},
url = {https://doi.org/10.3389/fimmu.2025.1601670}
}RIS
TY - JOUR TI - An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies. AU - Mazein A AU - Lopata O AU - Reiche K AU - Sewald K AU - Alb M AU - Sakellariou C AU - Gogesch P AU - Morgan H AU - Neuhaus V AU - Pham NN AU - Sommer C AU - Perkins E AU - Fogal B AU - Shoaib M AU - Schneider R AU - Satagopam V AU - Ostaszewski M. PY - 2025 JO - Front Immunol DO - 10.3389/fimmu.2025.1601670 UR - https://doi.org/10.3389/fimmu.2025.1601670 ER -
APA
A, M., O, L., K, R., K, S., M, A., C, S., P, G., H, M., V, N., NN, P., C, S., E, P., B, F., M, S., R, S., V, S., & M., O. (2025). An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies.. Front Immunol. https://doi.org/10.3389/fimmu.2025.1601670
Source records
- europe-pmc · retrieved 2026-09-27T12:24:03.680Z
- doaj · retrieved 2026-09-27T12:24:03.670Z